Skip to main content
AAN.com
Articles
October 31, 2012

Video game–based coordinative training improves ataxia in children with degenerative ataxia

November 13, 2012 issue
79 (20) 2056-2060

ABSTRACT

Objective:

Degenerative ataxias in children present a rare condition where effective treatments are lacking. Intensive coordinative training based on physiotherapeutic exercises improves degenerative ataxia in adults, but such exercises have drawbacks for children, often including a lack of motivation for high-frequent physiotherapy. Recently developed whole-body controlled video game technology might present a novel treatment strategy for highly interactive and motivational coordinative training for children with degenerative ataxias.

Methods:

We examined the effectiveness of an 8-week coordinative training for 10 children with progressive spinocerebellar ataxia. Training was based on 3 Microsoft Xbox Kinect video games particularly suitable to exercise whole-body coordination and dynamic balance. Training was started with a laboratory-based 2-week training phase and followed by 6 weeks training in children’s home environment. Rater-blinded assessments were performed 2 weeks before laboratory-based training, immediately prior to and after the laboratory-based training period, as well as after home training. These assessments allowed for an intraindividual control design, where performance changes with and without training were compared.

Results:

Ataxia symptoms were significantly reduced (decrease in Scale for the Assessment and Rating of Ataxia score, p = 0.0078) and balance capacities improved (dynamic gait index, p = 0.04) after intervention. Quantitative movement analysis revealed improvements in gait (lateral sway: p = 0.01; step length variability: p = 0.01) and in goal-directed leg placement (p = 0.03).

Conclusions:

Despite progressive cerebellar degeneration, children are able to improve motor performance by intensive coordination training. Directed training of whole-body controlled video games might present a highly motivational, cost-efficient, and home-based rehabilitation strategy to train dynamic balance and interaction with dynamic environments in a large variety of young-onset neurologic conditions.

Classification of evidence:

This study provides Class III evidence that directed training with Xbox Kinect video games can improve several signs of ataxia in adolescents with progressive ataxia as measured by SARA score, Dynamic Gait Index, and Activity-specific Balance Confidence Scale at 8 weeks of training.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (appendix_e-1.docx)
File (appendix_e-2.doc)
File (appendix_e-3.doc)
File (appendix_e-4.doc)
File (appendix_e-5.doc)
File (appendix_e-6.doc)
File (video_games_in_cerebellar_ataxia.pdf)

REFERENCES

1.
Ilg W, Synofzik M, Brötz D, Burkard S, Giese MA, Schöls L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009;73:1823–1830.
2.
Ilg W, Brötz D, Burkard S, Giese MA, Schöls L, Synofzik M. Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord 2010;25:2239–2246.
3.
Miyai I, Ito M, Hattori N, et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair 2012;26:515–522.
4.
Marsden J, Harris C. Cerebellar ataxia: pathophysiology and rehabilitation. Clin Rehabil 2011;25:195–216.
5.
Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717–1720.
6.
Schmitz-Hübsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008;71:982–989.
7.
Yack HJ, Berger RC. Dynamic stability in the elderly: identifying a possible measure. J Gerontol 1993;48:M225–M230.
8.
Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol 1995;50A:M28–M34.
9.
Ilg W, Golla H, Thier P, Giese MA. Specific influences of cerebellar dysfunctions on gait. Brain 2007;130:786–798.
10.
Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007;6:245–257.

Information & Authors

Information

Published In

Neurology®
Volume 79Number 20November 13, 2012
Pages: 2056-2060
PubMed: 23115212

Publication History

Received: February 29, 2012
Accepted: July 24, 2012
Published online: October 31, 2012
Published in print: November 13, 2012

Permissions

Request permissions for this article.

Disclosure

W. Ilg, C. Schatton, and J. Schicks report no disclosures relevant to the manuscript. M. Giese received research funding from the Deutsche Forschungsgemeinschaft, the EU, the Volkswagen Foundation, and HFSP-Grant. L. Schöls served on a scientific advisory board for Takeda Pharma; and received research support from Santhera Pharmaceuticals, the Deutsche Forschungsgemeinschaft, the German Research Council (BMBF), the EU, the E-RARE program, the Volkswagen Foundation, and the HSP-Selbsthilfegruppe Deutschland eV. M. Synofzik received a research grant by the Volkswagen Foundation, a travel grant by the Movement Disorders Society, and speaker honoraria from Fresenius Kabi. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

Winfried Ilg, PhD
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Cornelia Schatton
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Julia Schicks, MD
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Martin A. Giese, PhD
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
editorial board member of journal Cognitive Neurodynamics
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Deutsche Forschungsgemeinschaft [SFB 555 (Co-PI) andGI305/2(PI)], European Union [CobolFP6-NEST-2005-Path-IMP-043403(Co-PI)];[SEARISE FP7-ICT-215866(Co-PI)],[EC FP7-ICT-249858 TANGO], [ECFP7-ICT-248311 AMARSi]
Research Support, Foundations and Societies:
1.
Volkswagen Foundation [I/76556-1(PI)] HFSP-Grant [RGP54/2004 (Co-PI)]
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ludger Schöls, MD
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Scientific Advisory Board for Takeda Pharma in 2007
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
I served as an editorial board member for MovementDisorders 2006-2008
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
As participant of the MICONOS trial I received fees fromSanthera Pharmaceuticals
Research Support, Government Entities:
1.
I received the following grants: PI: PET in SCA (grant SCHO754/3-1), DFG: 2007-2009, PI: New locus for adHSP (grant SCHO754/4-1), DFG: 2008-2010, PI: Genetic disroders in Arab Societies (grantSCHO754/5-1), DFG: 2011-2013, PI: Leukodystrophies in adulthood (Leukonet, grant 01GM0644), BMBF: 2004-2011, PI: mitoMORPH (mitoNET, grant 01GM0864), BMBF: 2008-2011, Co-Investigator: EUROSCA (LSHM-CT-2004-503304), EU: 2004-2009, PI: EUROSPA (01GM0807) EU/BMBF: 2008-2011, Co-PI: RISCA (01GM0820) EU/BMBF: 2008-2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
I received additional funding from the HSP-Selbsthilfegruppe Deutschland eV.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Matthis Synofzik, MD
From the Department of Cognitive Neurology (W.I., C.S., M.A.G.), Hertie Institute for Clinical Brain Research; Centre for Integrative Neuroscience (CIN) (W.I., C.S., M.A.G.); Department of Neurodegeneration (J.S., L.S., M.S.), Hertie Institute for Clinical Brain Research and Center of Neurology; and German Research Center for Neurodegenerative Diseases (DZNE) (J.S., L.S., M.S.), University of Tübingen, Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Movement Disorders Society (Non profit entity), TravelGrant 2011.(2) Fresenius Kabi (commercial entity), speakers honoraria.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Oliver-Vaihinger-Fonds, Stiftung für kranke Kinder, Tübingen;(2) Ataxia UK (3)Ataxia Ireland(4) German Hereditary Ataxia Foundation (DHAG)(5) Volkswagen Stiftung (VW II/85 158)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence & reprint requests to Dr. Ilg: [email protected]
Study funding: Supported by the Oliver-Vaihinger-Fonds, Stiftung für kranke Kinder, Tübingen, Germany; Ataxia UK; Ataxia Ireland; the German Hereditary Ataxia Foundation (DHAG); and the Volkswagenstiftung (grant VW II/85 158 awarded to M.S.)
Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.

Author Contributions

W. Ilg: design and conceptualization of the study, analysis and interpretation of the data, drafting the manuscript. C. Schatton: analysis and interpretation of the data. J. Schicks: analysis and interpretation of the data. M. Giese: interpretation of the data, revising the manuscript. L. Schöls: conceptualization of the study, revising the manuscript. M. Synofzik: design and conceptualization of the study, analysis and interpretation of the data, drafting the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Adapted Physical Activity and Ataxia, Ataxia - Practice Essentials and Interventions, (2024).https://doi.org/10.5772/intechopen.111792
    Crossref
  2. Recovery of balance and walking in people with ataxia after acute cerebral stroke: study protocol for a prospective, monocentric, single-blinded, randomized controlled trial, Frontiers in Stroke, 3, (2024).https://doi.org/10.3389/fstro.2024.1388891
    Crossref
  3. The Growing Role of Telerehabilitation and Teleassessment in the Management of Movement Disorders in Rare Neurological Diseases: A Scoping Review, Telemedicine and e-Health, 30, 9, (2419-2430), (2024).https://doi.org/10.1089/tmj.2023.0702
    Crossref
  4. Gamification and neurological motor rehabilitation in children and adolescents: a systematic review, Neurología (English Edition), 39, 1, (63-83), (2024).https://doi.org/10.1016/j.nrleng.2023.12.006
    Crossref
  5. Ludificación y neurorrehabilitación motora en niños y adolescentes: revisión sistemática, Neurología, 39, 1, (63-83), (2024).https://doi.org/10.1016/j.nrl.2021.02.011
    Crossref
  6. 10. Temps et danse dans les anomalies rares de développement du cervelet, Maladies rares, (167-184), (2023).https://doi.org/10.3917/eres.gargi.2023.01.0167
    Crossref
  7. The Effect of the Physiotherapy Program in Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay (ARSACS): A Case ReportCharlevoix Saguenay Otozomal Resesif Spastik Ataksiside (ARSACS) Fizyoterapi Programının Etkinliği: Bir Olgu Sunumu, İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, 19, (340-346), (2023).https://doi.org/10.38079/igusabder.1159162
    Crossref
  8. Investigating Visual Perception Impairments through Serious Games and Eye Tracking to Anticipate Handwriting Difficulties, Sensors, 23, 4, (1765), (2023).https://doi.org/10.3390/s23041765
    Crossref
  9. A Proof of Concept Combined Using Mixed Reality for Personalized Neurorehabilitation of Cerebellar Ataxic Patients, Sensors, 23, 3, (1680), (2023).https://doi.org/10.3390/s23031680
    Crossref
  10. Effectiveness of rehabilitation intervention in persons with Friedreich ataxia, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1270296
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share